RxSight, Inc. (NASDAQ:RXST) CFO Sells $526,900.00 in Stock

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total transaction of $526,900.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at approximately $734,393.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

RxSight Trading Up 3.4 %

RXST stock opened at $61.68 on Friday. The stock’s 50 day simple moving average is $52.59 and its 200 day simple moving average is $42.56. RxSight, Inc. has a 12-month low of $18.09 and a 12-month high of $61.85. The firm has a market cap of $2.29 billion, a P/E ratio of -43.13 and a beta of 1.21.

RxSight (NASDAQ:RXST) last issued its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. The company had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. On average, research analysts forecast that RxSight, Inc. will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on RXST shares. JPMorgan Chase & Co. boosted their target price on shares of RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of RxSight in a research note on Thursday, April 11th. Stifel Nicolaus raised their price target on shares of RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Finally, Oppenheimer upped their price target on shares of RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight presently has a consensus rating of “Buy” and an average target price of $49.63.

Institutional Investors Weigh In On RxSight

Several institutional investors and hedge funds have recently bought and sold shares of the business. Lisanti Capital Growth LLC raised its position in shares of RxSight by 108.6% during the 3rd quarter. Lisanti Capital Growth LLC now owns 123,205 shares of the company’s stock worth $3,436,000 after purchasing an additional 64,130 shares during the period. Trexquant Investment LP grew its stake in RxSight by 82.9% during the 3rd quarter. Trexquant Investment LP now owns 47,230 shares of the company’s stock worth $1,317,000 after buying an additional 21,401 shares during the last quarter. Vanguard Group Inc. increased its position in RxSight by 21.6% in the third quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after buying an additional 255,150 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in RxSight by 263.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 243,346 shares of the company’s stock valued at $6,787,000 after buying an additional 176,451 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of RxSight by 17.3% during the third quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock valued at $67,989,000 after acquiring an additional 359,295 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.